Literature DB >> 25438959

Loss of N-cadherin is associated with loss of E-cadherin expression and poor outcomes of liver resection in hepatocellular carcinoma.

Yang-an Liu1, Bin-yong Liang2, Yan Guan2, Jian You3, Ling Zhu4, Xiao-ping Chen2, Zhi-yong Huang5.   

Abstract

BACKGROUND: Our previous study suggested that N-cadherin was downregulated in hepatocellular carcinoma (HCC). Our aim in this study was to investigate the correlation between N- and E-cadherin expression in HCC and its clinical significance.
METHODS: Eighty-six patients with HCC undergoing liver resection were retrospectively studied. N- and E-cadherin expression in HCC and adjacent liver tissue were investigated using immunohistochemistry and immunofluorescence. The correlation between the expression status of both cadherins and surgical outcomes was analyzed.
RESULTS: In 23 patients negative for E-cadherin expression, 19 of them (82.6%) were also negative for N-cadherin expression. In 30 patients with heterogeneous expression of E-cadherin, 20 of them (66.7%) also had heterogeneous expression of N-cadherin. In 33 patients with uniformly positive expression of E-cadherin, 19 of them (57.6%) also had uniformly positive expression of N-cadherin. Therefore, there was a positive correlation between expression patterns of N- and E-cadherins. Concurrent loss of both N- and E-cadherin expressions was significantly associated with absence of the tumor capsule, vascular invasion, and poor differentiation. The 1- and 3-y disease-free survival rates were 27% and 9%, respectively, and the 1- and 3-y overall survival rates were 64.3% and 14.3%, respectively, in patients with concurrent loss of both cadherins, which were significantly worse than those with concurrent uniformly positive expression or heterogeneous expression of both cadherins.
CONCLUSIONS: Loss of N-cadherin was positively correlated with loss of E-cadherin in HCC. Concurrent loss of both N- and E-cadherin expressions was associated with poor surgical outcomes of HCC patients undergoing liver resection.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E-cadherin; Expression; Hepatocellular carcinoma; N-cadherin; Survival

Mesh:

Substances:

Year:  2014        PMID: 25438959     DOI: 10.1016/j.jss.2014.09.031

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.

Authors:  Alexandra Drakaki; Maria Hatziapostolou; Christos Polytarchou; Christina Vorvis; George A Poultsides; John Souglakos; Vassilis Georgoulias; Dimitrios Iliopoulos
Journal:  BMC Cancer       Date:  2015-07-24       Impact factor: 4.430

Review 2.  Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis.

Authors:  Yong Luo; Ting Yu; Qiongwen Zhang; Qingyu Fu; Yuzhu Hu; Mengmeng Xiang; Haoning Peng; Tianying Zheng; Li Lu; Huashan Shi
Journal:  Eur J Clin Invest       Date:  2018-02-25       Impact factor: 4.686

3.  Role for the transcriptional activator ZRF1 in early metastatic events in breast cancer progression and endocrine resistance.

Authors:  Aysegül Kaymak; Sergi Sayols; Thaleia Papadopoulou; Holger Richly
Journal:  Oncotarget       Date:  2018-06-19

4.  Long non-coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E-cadherin, N-cadherin, and vimentin.

Authors:  Shu Liao; Chaxiu Yu; Hucheng Liu; Congkai Zhang; Yong Li; Xiaojun Zhong
Journal:  Onco Targets Ther       Date:  2019-05-24       Impact factor: 4.147

5.  KLF4-Mediated CDH3 Upregulation Suppresses Human Hepatoma Cell Growth and Migration via GSK-3β Signaling.

Authors:  Li Li; Shijun Yu; Qiong Wu; Ning Dou; Yandong Li; Yong Gao
Journal:  Int J Biol Sci       Date:  2019-03-10       Impact factor: 6.580

6.  MicroRNA-206 suppresses growth and metastasis of breast cancer stem cells via blocking EVI-1-mediated CALR expression.

Authors:  Dapeng Sun; Chenguang Li; Fengxiang Zhang
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

7.  miR-338-3p inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma cells.

Authors:  Jing-Song Chen; Li-Li Liang; Hong-Xu Xu; Fan Chen; Shun-Li Shen; Wei Chen; Lian-Zhou Chen; Qiao Su; Long-Juan Zhang; Jiong Bi; Wen-Tao Zeng; Wen Li; Ning Ma; Xiao-Hui Huang
Journal:  Oncotarget       Date:  2016-06-17

8.  Bioinformatics analysis of LINC01554 and its co‑expressed genes in hepatocellular carcinoma.

Authors:  Ling Li; Kang Huang; Zhongshan Lu; Huijia Zhao; Hao Li; Qifa Ye; Guizhu Peng
Journal:  Oncol Rep       Date:  2020-09-25       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.